Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The CAMPFIRE study, officially titled ‘A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor,’ aims to assess the safety and efficacy of ramucirumab combined with chemotherapy in treating desmoplastic small round cell tumor (DSRCT) in children and young adults. This study is part of a larger effort to accelerate cancer treatment development for younger populations.
The intervention involves testing ramucirumab, an intravenous drug, in combination with oral cyclophosphamide and intravenous vinorelbine, against a comparator group receiving only cyclophosphamide and vinorelbine. The goal is to determine the effectiveness of this combination in improving patient outcomes.
The study employs a randomized, parallel intervention model without masking, focusing primarily on treatment. This design allows for a clear comparison of the treatment’s impact on disease progression and survival rates.
Key dates for the study include its start on January 22, 2020, with primary results expected by June 12, 2025, and the latest update submitted on July 18, 2025. These timelines are crucial for tracking the study’s progress and anticipating results.
This update could influence Eli Lilly’s stock performance positively, as successful results may enhance investor confidence and market position, especially in the competitive oncology sector. The study’s outcomes could also impact the broader industry by setting new standards for pediatric cancer treatment.
The study is ongoing, and further details are available on the ClinicalTrials portal.